December 16, 2024 14:02 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bangladesh likely to hold national polls in late 2025 or early 2026, says Yunus in Victory Day speech | Constitution stood test of time: Nirmala Sitharaman in Rajya Sabha | PM Museum requests Rahul Gandhi to return Pandit Nehru's historical letters | Indian tabla maestro Zakir Hussain dies at 73 in San Francisco, confirms family | Kolkata woman strangled, beheaded and chopped into pieces for refusing brother-in-law's advances | Arvind Kejriwal, CM Atishi to contest Delhi polls from current constituencies | Atul Subhash suicide case: Wife Nikita, her mother and brother arrested | Pushpa 2 stampede: Allu Arjun walks out of jail, actor's lawyer slams delay in release | Donald Trump intends to end 'inconvenient' and 'very costly' Daylight Saving Time | Suchir Balaji: Indian-origin former OpenAI researcher found dead at US apartment
Dr Reddy's labs

Dr Reddy's Labs net profit declines 12.6 pc to Rs 579.3 cr in June qtr

| @indiablooms | Jul 29, 2020, at 08:47 pm

Hyderabad/IBNS: Drug manufacturer Dr Reddy's Labs has said its net profit in the June quarter declined 12.60 per cent to Rs 579.3 crore compared with Rs 662.8 crore during the same quarter last month.

The company said its gross margin rose to 56 per cent from 51.7 per cent while its while its revenue from operations rose 15 per cent annually to Rs 4,417.5 crore.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) or operating profit rose 2 per cent to Rs 1,162 crore.

The Hyderabad based company said revenue from India plummeted 10 per cent annually to Rs 630 crore due to lower prescriptions generated and decline in patients visiting clinics and pharmacies.

"The current quarter's financial performance has been strong across all parameter. l am glad that we have been able to serve our patients well and ensured continuity of business operations despite the challenging times. We have started integration and acquired business from Wockhardt and executed two important licencing arrangements for treatment options for COVID-19. Currently, we are working towards bringing both these drugs to multiple markets," G V Prasad, co-chairman and managing director of Dr Reddy's labs  said in a statement

Its revenue from North America, its biggest market, rose 6 per cent to Rs 1730 crore, mainly due to new products and favourable foreign exchange rate, which was offset by price erosion.

"Our operations have continued without much impact. We continued our engagement with doctors through digital channels, ensured regular supplies of our products to meet with the market demand and continued our R&D activities including few projects pertaining to COVID-19," Dr Reddy's Labs said.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.